home / stock / rnlx / rnlx news


RNLX News and Press, Renalytix AI plc From 09/07/23

Stock Information

Company Name: Renalytix AI plc
Stock Symbol: RNLX
Market: NASDAQ
Website: renalytix.com

Menu

RNLX RNLX Quote RNLX Short RNLX News RNLX Articles RNLX Message Board
Get RNLX Alerts

News, Short Squeeze, Breakout and More Instantly...

RNLX - Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the ...

RNLX - Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical group, to help advance the use of FDA authorized kidneyintelX.dkd™ in mitigating u...

RNLX - Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 dia...

RNLX - APLS, QNRX and RNLX among pre-market losers

2023-07-17 08:16:34 ET Quoin Pharmaceuticals ( QNRX ) -91% . BYND Cannasoft Enterprises ( BCAN ) -47% . Apellis Pharmaceuticals ( APLS ) -33% . Baosheng Media Group Holdings Limited ( BAOS ) -13% . Ebix ( EBIX ) -11% after clarific...

RNLX - Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool

2023-07-16 02:49:02 ET Summary Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, partnerships, and a sales team. The KidneyIntelX platform combines a blood test and data from patient...

RNLX - Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CIT...

RNLX - CCCC and AFRM among pre-market losers

2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...

RNLX - BTBT, ONCY and AMRX among pre-market losers

2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...

RNLX - Understanding Penny Stocks Breakout Patterns: 3 Tips 

2023-07-05 06:00:00 ET 3 Tips for Understanding Breakout Patterns With Penny Stocks Trading penny stocks can be an exciting and profitable endeavor for those who understand the game. Among the various strategies used by traders, one of the most intriguing is the identification of breako...

RNLX - Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, annou...

Previous 10 Next 10